VK-2019

Overview

VK-2019 is an investigational small-molecule inhibitor of EBV EBNA1, the viral nuclear antigen that drives NF-κB/MAPK/PI3K-AKT signaling and is required for EBV episome maintenance. It is evaluated in EBV-positive nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• VK-2019 EBNA1 inhibitor in EBV+ R/M NPC (NCT04925544, n=22): ORR 4.5% — limited single-agent activity observed; EBNA1 inhibition remains a proof-of-concept target PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.